Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.4052W HIGH $4.64
Volume
40.89 K
Value Traded
41.45 K
Short % Float
1.71%
+1.88%Week
+24.71%1 Month
+27.65%3 Month
-19.33%6 Month
-99.99%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
14.46 M
EPS (TTM)
-1.69
P/E Ratio
-
Ent. Value
10.97 M
Total Shares
6.66 M
Float Shares
5.66 M
Insiders
15.14%
Institutions
14.53%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SINT Catalyst Timeline
Dated clinical, regulatory and corporate events for SiNtx Technologies, Inc.
Past FDA Catalysts and PDUFA Decisions
How SINT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
SiNtx Technologies, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SINT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Elmore Robert RyanOfficer (President) | Grant/Award | 4,910 4,910 held | $2.89 | 04/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SINT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SINT for Q2 2026. | ||||
SINT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SINT ranks across every disease it competes in
Competitive Position is a premium feature
See how SINT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSINT News
SINT▲ +7.7%on this news
SiNtx Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market
SINTX Technologies, Inc. has announced a capital raise of approximately $5.0 million, including a $4.5 million private placement priced at-the-market. The offering involves issuing 1,882,845 shares of common stock along with corresponding warrants to accredited investors. The funds are earmarked for general corporate purposes, especially in advancing the company's silicon nitride technology. The financing reflects strong investor support and is expected to enhance SINTX's strategic capabilities in the medical application sector.
Read more →SINT▼ -21.2%on this news
SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride-PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants
SINTX Technologies has signed a significant supply agreement with EVONIK to manufacture its proprietary silicon nitride-PEEK (SiN/PEEK) compound. This collaboration allows for the immediate production of AI-assisted, 3D-printed, patient-specific implants at SINTX's facility in the U.S. The agreement will enable SINTX to respond to physician requests for humanitarian-use vertebral body replacement implants, addressing critical needs in trauma and oncology. The SiN/PEEK compound is anticipated to offer advantages over standard PEEK materials.
Read more →SINT▼ -10.8%on this news
SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies
SINTX Technologies, Inc. reported a pivotal business update for the third quarter of 2025, highlighting key achievements including FDA clearance for its SINAPTIC Foot & Ankle Osteotomy Wedge System and its first commercial revenue from OsseoSculpt. The company's financial highlights show a reduction in operating expenses and improved liquidity through a recent financing activity. However, revenue has decreased compared to the previous year, raising concerns despite strong operational efficiencies and portfolio expansions. Looking ahead, SINTX plans to focus on launching the SINAPTIC wedge system and expanding clinical engagement.
Read more →SINT▼ -5.8%on this news
SiNtx Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices Material Science Meets Surgical Precision in Groundbreaking New Platform in Reconstructive Foot & Ankle Surgery Market
SINTX Technologies has submitted a 510(k) premarket notification to the FDA for its silicon nitride osteotomy wedges, marking its entry into the reconstructive foot and ankle market. The company emphasizes the advanced biomaterial's benefits, including improved bone integration and reduced infection rates, as well as proprietary implant designs aimed at enhancing surgical efficiency. This development is projected to drive significant revenue growth, with expectations for strong early adoption by healthcare providers. However, the company acknowledges that the approval process and commercialization may encounter uncertainties.
Read more →SINTSiNtx Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities
SINTX Technologies announced the acquisition of SiNAPTIC Holdings' surgical business assets, enabling entry into the $1.3 billion foot and ankle fusion market. This acquisition includes all intellectual property and product designs related to six differentiated implant systems, aiming to accelerate commercial growth. The deal, viewed as transformative, will likely shift SINTX's focus from R&D towards revenue generation, assisted by SiNAPTIC's experienced team. However, achieving success will depend on effective commercialization and navigating regulatory hurdles.
Read more →SINT▼ -7.6%on this news
SiNtx Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market
SINTX Technologies has announced the issuance of an international patent for silicon nitride applications in agriculture, specifically for antimicrobial treatment and plant protection. The company is expanding into the agribiotech market with the formation of a subsidiary, SINTX Agribiotech, which will focus on developing sustainable agricultural technologies. Expected growth in the global antimicrobial fertilizer market highlights the potential for silicon nitride, which has shown promising results in preventing crop diseases. Nevertheless, the company acknowledges that commercialization challenges could impact future success.
Read more →SINTSiNtx Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization Lake City, UT - May 15, 2025 - SINTX Technologies, Inc. (NASDAQ: SINT), an advanced ceramics company pioneering medical
SINTX Technologies, Inc. has announced a business update detailing its strategic shift toward medical device commercialization, focusing on silicon nitride applications. The company reported improved financials, including a cash increase and reduced operating costs. Highlighting advanced research programs and partnerships with medical OEMs, SINTX aims to meet critical healthcare needs. However, the transition carries risks related to product commercialization and market acceptance.
Read more →SINT▼ -19.6%on this news· ran to -47% by day 3
SiNtx Technologies Announces $5 Million Private Placement Priced At-the-Market under Nasdaq Rules
SINTX Technologies, Inc. announced the completion of a $5 million private placement under Nasdaq rules. This deal involved the sale of 1,449,287 shares at a price of $3.45 each, along with unregistered warrants. The company plans to utilize the proceeds for working capital and will file registration statements with the SEC for resale of the shares. Wainwright & Co. acted as the exclusive placement agent for this offering.
Read more →SINTSINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT
SINTX Technologies has announced the appointment of Gregg R. Honigblum as Chief Strategy Officer. Honigblum, a seasoned healthcare executive with over 35 years of experience, will lead the company's strategic growth initiatives and enhance investor relations. His background includes significant fundraising for healthcare technologies and involvement in early-stage capital roles. The company's leadership expresses confidence that his experience will help elevate SINTX’s market position amidst ongoing uncertainties in the industry.
Read more →SINT▲ +55.9%on this news· ran to +111% by day 3shared move
SINTX Technologies Announces Stock Repurchase Program Salt Lake City, UT
SINTX Technologies, Inc. has announced a stock repurchase program authorized by its Board of Directors to buy back up to $500,000 of the company's outstanding common stock. This program, which represents approximately 20% of total outstanding shares, reflects SINTX's confidence in its strategic initiatives and commitment to enhancing shareholder value. The stock repurchases will depend on market conditions and other factors, with management retaining discretion over timing and amounts. This program aligns with SINTX's ongoing efforts to optimize its capital structure and return capital to shareholders.
Read more →SINTSINTX Technologies Announces Appointment of Eric K. Olson as Chief Executive Officer Salt Lake City, Utah.
SINTX Technologies has appointed Eric K. Olson as its new CEO and President, succeeding Dr. B. Sonny Bal, who will remain as Chairman of the Board. Olson, a seasoned entrepreneur with over 30 years in the medical device field, previously held executive roles at SINTX, aiding in its IPO in 2014. The Board expressed confidence in Olson's leadership skills to drive the company's growth and enhance shareholder value. Additionally, Gregg Honigblum has been designated as Board Advisor, leveraging his extensive financial advisory experience.
Read more →SINTSINTX Technologies Regains Compliance with Nasdaq Bid Price Requirement Salt Lake City, Utah.
SINTX Technologies, Inc. has announced that it has regained compliance with the Nasdaq bid price requirement, a significant milestone for the company. The compliance was confirmed in a notice from Nasdaq on June 11, 2024, effectively closing a previously announced listing matter. However, SINTX remains under a Mandatory Panel Monitor for a year and must maintain the minimum bid price to avoid potential delisting.
Read more →SINT▼ -13.5%on this news· ran to -58% by day 3
SINTX TECHNOLOGIES Announces Reverse Stock Split Effective
SINTX Technologies, Inc. has announced a 1-for-200 reverse stock split effective May 28, 2024. This action aims to bring the company into compliance with the Nasdaq Capital Market's minimum bid price requirements. The reverse split will reduce the number of outstanding shares significantly, from approximately 123 million to about 0.6 million, while not altering the authorized shares or par value. All stockholders will be impacted uniformly, and fractional shares will be rounded up to whole shares. Concerns remain regarding the company's compliance status and market perception following this decision.
Read more →SINT▼ -21.6%on this news· ran to -49% by day 3
SINTX Technologies Announces Proposed Public Offering of Common Stock
SINTX Technologies has announced its intent to conduct a public offering of common stock. The proceeds from the offering are planned to support working capital and general corporate purposes, although the completion of this offering is contingent on market conditions. There are no guarantees regarding the offering's size or terms. SINTX has been engaging in strategic acquisitions to further its growth in advanced ceramics and medical applications.
Read more →SINT▼ -34.5%on this news
E xhibit 99.1 SINTX TECHNOLOGIES ANNOUNCES PRICING OF $4.0
SINTX Technologies, Inc. has announced the pricing of its public offering of 16 million units, each priced at $0.25. The offering includes common stock and warrants. Proceeds are expected to be approximately $4 million before costs, with the offering set to close on February 2, 2024. The company emphasizes that the offering is made in accordance with a recently effective SEC registration statement.
Read more →SINTSINTX TECHNOLOGIES SHARES SELECT PRELIMINARY Q4 2023 AND FULL YEAR 2023
SINTX Technologies, Inc. has reported preliminary unaudited revenues of approximately $902,000 for Q4 2023 and $2.6 million for the full year 2023. This marks an 18% increase in Q4 revenue year-over-year and a 68% increase compared to 2022. The growth has been attributed to new product adoption across various markets, including aerospace and biomedical sectors. SINTX also expects continued revenue growth in 2024, particularly by re-engaging in the ballistic and body armor market as demand remains strong.
Read more →SINT▼ -8.5%on this news
SINTX TECHNOLOGIES ENTERS A LONG-TERM
SINTX Technologies, Inc. has entered a long-term supply agreement to provide silicon nitride components for jet engines, marking the company's expansion beyond biomedical implants into aerospace applications. This agreement follows a two-year process of qualification of SINTX's operational and quality management systems. Although the deal allows for flexibility in supply without minimum requirements, projected revenues are modest, estimated under $0.25 million annually. The agreement extends through 2026, with an option for renewal by the customer based on demand forecasts.
Read more →SINTSINTX Technologies Awarded Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants
SINTX Technologies, Inc. has been awarded a Phase II grant of $1,972,826 by the NIH to further develop its 3D printed silicon nitride-polyetheretherketone (SN-PEEK) spinal implants. This grant follows a successful Phase I project, which demonstrated the reliability and biocompatibility of these composite implants. Over the next 24 months, SINTX will collaborate with the University of Pennsylvania School of Veterinary Medicine to validate the design and perform rigorous testing. The completion of this project aims to support FDA regulatory clearance and advance infection prevention claims for these spinal devices.
Read more →SINTSINTX Technologies Announces Pricing of $12.0 Million Public Offering
SINTX Technologies, Inc. has announced the pricing of its public offering, consisting of 2,150,000 units priced at $5.60 each. The offering is anticipated to generate approximately $12.0 million before expenses, expected to close on February 10, 2023. Each unit includes common stock and warrants, which will be immediately exercisable upon issuance. The offering is being conducted in accordance with SEC regulations, and while it presents opportunities for the company, there are inherent risks in product commercialization and acceptance in the market.
Read more →About SiNtx Technologies, Inc.
Headquarters1885 WEST 2100 STREET, SALT LAKE CITY, UT, 84119
BIOPHARMAWATCH ELITE PLUS
Trade the next SINT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime